Recent advances in human immunodeficiency virus (HIV) vaccine design have resulted in induction of strong CD4 T-cell proliferative and polyfunctional cytokine responses, which are also characteristic for long-term non-progressing (LTNP) HIV-infected individuals. However, limited information is available on the persistence of these responses after infection. Results from studies in non-human primates indicate that vaccine-induced immune responses are partially maintained upon viral infection and differ from the responses seen in non-vaccinated animals that typically progress to disease. However, it is unclear how these partially preserved responses compare to immune responses that are acquired naturally by LTNP animals. In this study, immune-response profiles were compared between vaccinated animals that, upon SHIV 89.6p challenge, became infected but were able to control virus replication, and a group of animals having spontaneous control of this viral infection. Both groups were found to develop very similar immune responses with regard to induction of CD4 and CD8 T-cell polyfunctional cytokine responses, proliferative capacity and cytotoxic capacity, as measured by a standard 51 Cr release assay and more direct ex vivo and in vivo CTL assays. Hence, vaccinated animals that become infected, but control infection, appear to establish immune responses that are similar to those elicited by long-term non-progressors.
INTRODUCTION
Since the onset of the human immunodeficiency virus (HIV) epidemic more than three decades ago, more than 60 million persons are estimated to have become infected, of which the large majority typically progress to AIDS in the absence of anti-retroviral treatment. However, a small group of so-called 'long-term non-progressors' (LTNP) have been identified who, without treatment, remain clinically and immunologically stable for years (Cao et al., 1995; Muñoz et al., 1995; Pantaleo et al., 1995; Sheppard et al., 1993) , although some progression was found to occur on longer-term follow-up (Lefrère et al., 1997; Rodés et al., 2004) . More recently, an even smaller cohort (,1 % of HIV-infected people), termed 'ELITE controllers', was defined. They share a durable control of HIV replication, leading to plasma viral loads that are consistently ,50 RNA copies ml 21 (Deeks & Walker, 2007; Hubert et al., 2000) . Studies directed at identifying the mechanisms underlying viral control have shown no direct relationship with the presence of viral variants , indicating that host factors are of primary importance. Indeed, the association of certain MHC-class I and II alleles with low virus load (Giraldo-Vela et al., 2008; Harari et al., 2007; Kiepiela et al., 2004; Loffredo et al., 2007; Migueles et al., 2000; Yant et al., 2006) highlights a role for adaptive immune responses in the control of viral replication, although innate natural killer cell responses, involving killer-cell immunoglobulin-like receptor-MHC class I interactions (Martin et al., 2002) , as well as triggering of type I interferon release from plasmacytoid DC might play a key role as well (Soumelis et al., 2001) . A central role for CTL function in suppression of virus replication can be inferred from: (i) the observation that, in the acute phase of the infection, suppression of virus replication is preceded by an increase in HIV-specific CD8 T-cells, (ii) from observations on viral escape and (iii) from CD8 T-cell depletion experiments in simian immunodeficiency virus (SIV)-macaque infection models (Goulder et al., 1997; Schmitz et al., 1999) . In LTNP, CD8 responses are increased both in magnitude and breadth, and in part are directed to conserved epitopes or to epitopes that can only be mutated at a cost of viral fitness Altfeld et al., 2003 Altfeld et al., , 2006 Betts et al., 2001; Martinez-Picado et al., 2006) . Functional characterization of HIV-specific T-cell responses in LTNP has demonstrated an increased cytotoxic potential in the CD8 T-cell population. Also demonstrated was an increased proliferative capacity, and polyfunctional cytokine expression patterns, in CD4 as well as CD8 T-cells, relative to individuals characterized by progressive disease (Betts et al., 2006; Emu et al., 2005; Harari et al., 2004; Horton et al., 2006a; Migueles et al., 2002 Migueles et al., , 2008 Pereyra et al., 2008; Younes et al., 2003; Yue et al., 2004) .
These characteristic immune features encountered in LTNP have been taken as a guide to set reference standards for HIV-vaccine-induced T-cell responses. Indeed, recent vaccine trials have reported induction of polyfunctional CD4 and CD8 T-cell responses Precopio et al., 2007) . However, preservation of these responses after challenge is not well studied and is difficult to interpret since new responses emerge on a continuous basis (Horton et al., 2006b) . Studies in vaccinated rhesus macaques have been more extensive, reporting preservation of polyfunctionality in animals that could partially suppress virus replication (Acierno et al., 2006; Sun et al., 2008) , but also reporting a loss-of-function or skewing of immune responses through induction of multiple new specificities (Mattapallil et al., 2006; Vogel et al., 2001 Vogel et al., , 2002 . In none of these studies, however, have postinfection immune responses in vaccinated macaques been compared directly to responses seen in 'natural' controllers infected with exactly the same viral isolate. Here a group of rhesus macaques, which without antiviral treatment were able to suppress SHIV 89.6p replication to below 500 copies ml 21 for more than 140 weeks, were directly compared to a group of 'vaccine controller' animals that had been subjected to Tcell-directed HIV vaccine strategies. Both groups displayed not only similar HIV/SIV-specific CD4 and CD8 polyfunctional cytokine responses, but also similar proliferative responses and comparable CTL function.
RESULTS
Over the past decade, many vaccine-evaluation studies in macaques have been performed, at various centres, in which efficacy against viral challenge was evaluated by using recombinant SHIV 89.6p (Amara et al., 2001; Barouch et al., 2001; Doria-Rose et al., 2003; Egan et al., 2004; Koopman et al., 2008; Letvin et al., 2004; Mooij et al., 2004 Mooij et al., , 2008 Shiver et al., 2002) . Table 1 summarizes the general outcome of these studies at the BPRC, specifying the relative proportion of animals able to control virus load to ,500 copies ml 21 by week 40 after challenge, as well as the number of animals that developed symptoms of AIDS during the 40-70 week period of follow-up. Naive macaques of both Indian and Chinese origin progressed to disease, although, as also reported by others (Reimann et al., 2005) , macaques of Indian origin were less capable of controlling virus replication and more readily progressed to AIDS. In contrast, vaccinated animals showed, in both the Indian and Chinese origin groups, a large level of control of virus replication and rare disease development. It has been hypothesized that the immune-response patterns observed in naturally infected non-progressing individuals could similarly provide control of infection in vaccinated persons. However, it is not known whether immune responses are qualitatively and quantitatively comparable between unvaccinated 'natural' controllers and vaccinated controllers. To study this, a small group of animals (described in Table 2 ) was selected from the cohort for further follow-up (ranging from 65 to 195 weeks) and immunological analysis. Ten vaccinated animals that controlled infection, of which six were of Indian origin, were compared with seven 'natural' controllers, of which three were of Indian origin (Table 2 ). For comparison, five progressor animals (all of Indian origin) were also included.
Vaccinated and 'natural' controllers of infection have comparable cytokine and proliferative responses during chronic infection
In the chronic phase of the infection (weeks 39-150 after challenge), six of ten vaccinated controllers and all seven 'natural' controllers showed a positive response against SIV Gag, as measured by an interferon gamma (IFN-c) ELISpot assay, while none of the progressor animals showed a positive response (Table 2 ). Although the group of 'natural' controllers might be considered to have more uniform positive responses against SIV Gag, the differences from the group of vaccinated controllers are not significant (P50.10; Fisher's exact test), while both vaccinated and 'natural' controllers had significantly higher responses than the progressors (P50.04 and P50.001, respectively). Responses against HIV-1 Env were less prevalent and were Similar immune profiles in vaccinated vs 'natural' LTNPs seen in 3/10 vaccinated and 2/7 'natural', controller animals.
To define the nature of these responses further, an intracellular cytokine staining (ICS) assay was performed on samples obtained during the chronic phase of the infection, 39-150 weeks post-challenge. In this assay, antigen-specific induction of three cytokines was measured, i.e. (IFN-c), tumour necrosis factor alpha (TNF-a) and interleukin 2 (IL-2). These cytokines are considered to be important immune-response indicators, and simultaneous production of two or three cytokines, i.e. polyfunctional responses, has been associated with the effective control of virus replication (Betts et al., 2006; Harari et al., 2004) . As shown in Fig. 1 , SIV Gag-specific cytokine responses were seen both in the vaccinated and 'natural' controller groups, while the progressor animals were totally negative. In both of the controller groups, virus-specific responses were observed to be mediated by CD4 as well as CD8 T-cells. HIV Env-specific responses were only observed occasionally, both in the vaccinated as well as in the 'natural' controller group. There was no statistically significant difference between the vaccinated and 'natural' controller groups in either CD4 or CD8 T-cell-mediated SIV Gag or HIV-1 Env responses (Mann-Whitney test). However, in both controller groups, SIV Gag responses were significantly higher than in the progressor group. For HIV-1 Env, only the difference between the vaccinated controllers versus the progressors was statistically significant. Further analysis of cytokine expression (Fig. 2 ) demonstrated polyfunctional responses with a comparable distribution of single, double and triple IFN-c, IL-2 and TNF-a cytokine-producing CD4 and CD8 subsets in both the vaccinated and 'natural' controller groups (Mann-Whitney test). IFN-c single and IFN-c, IL-2 double cytokine-producing CD4 T-cells, as well as IFN-c single-producing CD8 T-cells, were significantly higher for the vaccinated and 'natural' controller group relative to the group of progressor animals while for other cytokine Origins of the animals are indicated (Ind, Indian; Chi, Chinese; Bur, Burmese rhesus macaque). The vaccine type used is also given (DNA-ISCOM, DNA prime-immune stimulating complex; DNA-MVA, DNA prime-modified vaccinia Ankara; DNA-NYVAC, and also the antigen that was incorporated in the vaccine (T, HIV-1 tat; E, HIV-1 env; G, SIV gag; P, SIV pol). Responses against SIV Gag peptides and HIV-1 Env peptides were determined in the chronic phase of the infection (39-150 weeks post-challenge) and are presented semi-quantitatively: -, negative with ,50 spots per 10 6 PBMC; +, positive with 50-100 spots per 10 6 PBMC; ++, strongly positive with .100 spots per 10 6 PBMC.
Animal Origin
Vaccine type Antigen Follow-up (weeks)
Chronic phase response 
I. Nieuwenhuis and others
combinations, whose levels were often of lower magnitude, these differences were not significant (Fig. 2) . Preservation of lymphoproliferative capacity is an important feature observed in human LTNP (Migueles et al., 2002) and was therefore analysed in this cohort on samples obtained during the chronic phase of the infection. Although the responses were rather low, the vaccinated and 'natural' controller animals did display similar levels of proliferation induction, upon SIV Gag as well as HIV-1 Env peptide stimulation, in the CD4 as well as CD8 T-cell populations (Fig. 3) . Proliferative capacity was difficult to establish in the progressor animals due to the small number of CD4 Tcells present, which further deteriorated during culture. In conclusion, the magnitude and composition of the cytokine responses, as well as induction of CD4 and CD8 T-cell proliferation, were not significantly different between the groups of vaccinated versus 'natural' controllers of virus replication.
Characterization of T-cell cytotoxic function in vaccinated versus 'natural' controllers of infection
The characteristic preservation of T-cell cytotoxic function in human LTNP (Harari et al., 2009; Migueles et al., 2008) prompted us to investigate this in an indirect culture-based assay, i.e. a 51 Cr-release assay, as well as in direct ex vivo and in vivo cytotoxicity assays. SIV Gag-specific CTL activity, measured in a 51 Cr-release assay where peptidestimulated in vitro-expanded cultures are tested against autologous peptide-loaded B-lymphoblastoid cell lines (B-LCL), was detected in 5/10 vaccinated controllers and 3/6 'natural' controllers (Table 3) . Although this assay has been used extensively to assess CTL function, the use of B-LCL as the target cell as well as the in vitro-expansion protocol may not accurately represent the actual level of CTLmediated elimination that virus-infected cells encounter in vivo. Therefore, a more direct in vivo elimination assay was developed in which autologous PBMC that were labelled with fluorescent dye were loaded with viral peptides and reinfused into the animal. Subsequently, elimination of the cells within a 24 h period was evaluated against a control of autologous PBMC loaded with control peptides (herpes simplex virus gD) and labelled with a different dye or with the same dye at a different intensity. In this 'in vivo cytotoxicity assay', high-intensity-labelled antigen-pulsed cells as well as low-intensity-labelled control cells could be detected immediately (10 min) after injection at approximately similar frequencies, whereas, 24 h later, in animals with specific CTL responses, the antigen-loaded population was diminished relative to the control population (an example of this analysis is shown in Supplementary Fig. S1 , available in JGV Online). As shown in Table 3 , the in vivo CTL assay confirmed the positive responses of the 51 Crrelease assay but generally showed higher levels of specific cell lysis, which may indicate that the in vivo assay is more sensitive. Furthermore, some of the negative cases in the 51 Cr-release assay did exhibit antigen-specific lysis in the in vivo CTL evaluation, resulting in detection of CTL activity in 6/7 tested vaccinated controllers and all six 'natural' controllers. Since these studies were performed with peptide pools covering the entire Gag sequence, which could include peptides with varying killing-triggering capacity, the studies were extended to the peptide-specific level, using a few select animals. Peptide mapping studies, which were based on the 51 Cr-release assay because it most closely resembles the in vivo CTL assay, demonstrated specific responses against GNYVHLPLSP in animal DVT and against YNTNILDVK in animal VH2 (Fig. 4) . Subsequently, in vivo CTL activity was evaluated in these animals using specific peptides (GNYVHLPLSP in animal DVT, and YNPNILDVK in animal VH2). For comparison, this technique was also used in an ex vivo setting where 'effector' PBMC were incubated for 24 h with autologous dye-labelled and peptide-loaded 'target' PBMC. PIPVGNIYR was used as a control peptide. In addition, ECX was included as a control animal that had shown no responses against either of these peptides in the 51 Cr-release assay (Fig. 4) . As shown in Fig. 5 , peptide- Crrelease data showed some reaction against this peptide as well (Fig. 4) , which could have become more prominent in the ex vivo and in vivo CTL assays because of their relatively higher sensitivities. In conclusion, in both groups, vaccinated controllers and 'natural' controllers, T-cell cytotoxic function was evident and comparable with regard to the strength of the responses as well as to the proportion of the animals that showed a positive response. These comparable results were obtained by the standard 51 Cr-release assay as well as by the more sensitive in vivo CTL assays.
Since Mamu-A*001, Mamu-B*008 and Mamu-B*017 have been associated with containment of SIV replication (Hel et al., 2002; Loffredo et al., 2007; Yant et al., 2006) , the animals were typed for MHC class I alleles (Supplementary  Table S1 ). Mamu-A*001 alleles were found in four animals: two vaccinated controller (EKK and WJ8) and two progressor animals (9068 and 96025). Mamu-B*008 was seen in one animal belonging to the progressor group (9068). Mamu-B*017 was not observed. On the basis of this distribution, it is unlikely that these particular alleles are confounding factors in this study.
DISCUSSION
Previous vaccine-evaluation studies in macaques have demonstrated preservation of CD4 T-cells and, more recently, maintenance of high-magnitude polyfunctional immune responses upon challenge with pathogenic SHIV 89.6p , relative to unvaccinated SHIV-infected control animals (Acierno et al., 2006; Sun et al., 2006 Sun et al., , 2008 . However, as in HIV-1-infected humans, some animals have spontaneous control of this infection without previous immunization or treatment (Reimann et al., 2005) . Here, we describe a similar group of so-called 'natural' controllers and compare their immune-response profiles with a group of vaccinated animals that control infection. Detailed analysis showed that Gag-and Env-specific cytokine induction, proliferative responses and cytotoxic T-cell function were comparable between the groups of 'natural' and vaccinated controllers.
The animals used in this study were selected from previous vaccine-evaluation studies and had received a combination of HIV-1 Tat, HIV-1 Env and SIV Gag/Pol immunogens or HIV-Tat alone, or had served as challenge control animals in the same study. SIV Gag-specific responses were readily detectable in almost all vaccinated animals when SIV Gag virus-like particles (VLP) were used as an antigen (not shown). Clear responses against the SIV mac251 Gag peptides were observed after challenge (Table 2 ) and were shown to be mediated by CD8, as well as CD4, T-cells (Fig. 1 ).
Our data, compiled from several vaccine evaluation studies, showed that spontaneous control of virus replication was relatively rare in unvaccinated rhesus macaques of Indian origin (21 %). However, control of virus replication to ,500 copies ml 21 was found in 46 % of the macaques of Chinese origin, thus partially supporting previous findings of reduced virus replication in these animals (Reimann et al., 2005) . In vaccinated animals, suppression of virus replication was relatively common, reaching 70 and 87 % in macaques of Indian and Chinese origin, respectively, and progression to AIDS was rare. Although it is conceivable that some of the animals in the vaccinated controller group that was studied here might have spontaneously controlled their infection, the data presented above indicate that this could only be expected for three out of the ten animals, which, in view of the presented data, would not have changed the outcome of the analysis. *Performed only against specific peptides and described in Fig. 5 .
Similar immune profiles in vaccinated vs 'natural' LTNPs
Previous studies have implicated reduced CD8 T-cell effector function in HIV-disease progression but shown high proliferative capacity, polyfunctional cytokine production, granzyme and perforin expression, and cytotoxic function in LTNP individuals (Appay & Rowland-Jones, 2002; Betts et al., 2006; Migueles et al., 2002 Migueles et al., , 2008 van Baarle et al., 2002) . Interestingly, these capacities are thought to be mediated by different memory subsets, with preponderant proliferation in the central memory compartment and cytotoxic function in the effector memory and effector cell compartments (Champagne et al., 2001; Sallusto et al., 1999) . The data presented here show similar levels of CD4 and CD8 T-cell proliferation and cytokine production in 'natural' versus vaccinated controllers. In order to compare CTL effector function between these groups, two fundamentally different assays were applied:
firstly, a classical in vitro
51
Cr-release assay, which requires prior cell expansion and that monitors effector function elicited from the central memory compartment, and secondly, a direct ex vivo and in vivo cytotoxicity assay that monitors immediate effector function and which is probably mediated by the effector and effector memory compartment (Oehen & Brduscha-Riem, 1998) . In both the 'natural' controller group and the vaccinated controller group about half of the animals showed a positive response in the 51 Cr-release assays, while in both groups almost all of the animals exhibited cytotoxic activity as measured by the in vivo CTL assay. These data further support the overlapping response patterns already observed between 'natural' and vaccinated controllers. The high response levels observed in the in vivo CTL assay could be indicative of a dominant effector plus effector memory compartment. These data were further confirmed at the peptide-specific level (Fig. 5) . Detailed analysis of the MHC class I repertoire did not show a strong association between Mamu-A*001, -B*008 and -B*017 and resistance to disease, as was reported for several SIV strains (Hel et al., 2002; Loffredo et al., 2007; Yant et al., 2006) . Apart from the fact that we used a slightly different virus, most of our studies were conducted using animals of Chinese origin. Therefore, it is possible that in our cohort other MHC class I alleles contributed to resistance. Responses against individual 20-mer SIV Gag peptides were evaluated using a standard 51 Cr-release assay, giving a positive response against one peptide in animal DVT and two peptides in VH2. Further fine mapping by using 10-mer peptides showed responses in DVT to be directed against GNYVHLPLSP and in VH2 to be directed against YNPNILDVK. Fig. 5 . Peptide-specific cytotoxic capacity measured by ex vivo CTL and in vivo CTL assays. Animals received either autologous CFSEhigh-labelled cells loaded with specific CTL epitopes (GNYVHLPLSP for DVT and YNPNILDVK for VH2), or CFSE-low labelled cells loaded with the PIPVGNIYR control peptide. ECX received autologous CFSE-labelled PBMC loaded with either YNPNILDVK or PIPVGNIYR, which could both be considered control peptides (as they were not previously detectable by 51 Crrelease assay). The percentage of cell cytotoxicity in the ex vivo and in vivo CTL assays was calculated as 100 " [(number of CFSEpositive cells, specific peptide 24 h ¾ number of CFSE-positive cells, unpulsed 10 min )/(number of CFSE-positive cells, unpulsed 24 h ¾ number of CFSE-positive cells, specific peptide 10 min ) ¾ 100]. Specific cytotoxic activity ,10 % was considered negative.
In conclusion, the previously documented relative preservation of immune function in vaccinated animals upon SHIV 89.6p challenge (Acierno et al., 2006; Sun et al., 2006 Sun et al., , 2008 can also be obtained at comparable levels in animals that are able to control infection without prior immunization. Hence, the premise of using immunological analysis of LTNP cohorts to set standards for human vaccine trials seems valid.
METHODS
Animals. Mature captive-bred rhesus monkeys (Macaca mulatta) of Chinese and Indian origin were used in this study and one animal was of Burmese origin. The origin of the animals was confirmed by animal import permits, purchase records or pedigrees and by mitochondrial 12S rRNA analysis. They were housed in environmentally controlled conditions at the BPRC. The animals were negative for antibodies to SIV-1, simian type D retrovirus and simian T-cell lymphotropic virus at the initiation of the study. All animals were challenged with 50-100 MID 50 (50% monkey infectious dose) of the pathogenic cell-free SHIV stock '89.6p' by the intravenous route (1 ml per monkey). Of the 22 animals that were studied in detail, ten had received previous immunizations consisting of either a combination of HIV-1 Env, HIV-1 Tat and SIV Gag/Pol antigens or HIV-1 Tat alone, given either in a DNA prime-immune stimulating complex (ISCOM)-formulated protein combination or a DNA prime-modified vaccinia Ankara (MVA) viral-vector booster combination (Mooij et al., 2004) (Table  2 ). The control animals had either received control DNA, ISCOM or NYVAC vectors or were completely naive controls (Table 2) . Five animals developed disease; the other animals were able to control viral load at low levels and maintain stable CD4 + T-cell counts. During the course of the study, the animals were checked twice daily for appetite and general behaviour, and stools were checked for consistency. With each sedation for blood collection or immunization, the body weight and body temperature were measured. Animals developing opportunistic infections, a body weight loss of .10 %, persistently low CD4 counts and high viral loads were considered to be progressing to AIDS and were euthanized. The Institutional Animals Care and Use Committee approved study protocols developed according to strict international ethical and scientific standards and guidelines.
Determination of virus load and CD4 T-cell count. Plasma virus load was determined using a quantitative competitive-RNA RT-PCR using plasma from EDTA-treated blood samples as described previously by Ten Haaft et al. (1998) . To monitor changes in lymphocyte subset composition and CD4 T-lymphocyte count, flow cytometry was performed after SHIV 89.6p challenge as described by Koopman et al. (2004) .
MHC class I typing and restriction. Originally the MHC type (Mamu-A and -B) of the animals was determined using polyclonal sera raised by active immunizations. A cluster of positive typing reactions defines the serotypes. The nucleotide profiles and transcription status of the corresponding Mamu class I alleles which segregate with particular serotypes were described by Otting et al. (2005 Otting et al. ( , 2007 Otting et al. ( , 2008 .
ELISpot assay for IFNc secretion. PBMC (4610 6 ml
21
) were stimulated with either SIV mac239 Gag VLP (prepared by Dr R. Wagner, Regensburg University, Germany) as protein antigen or with SIV mac239 -Gag (NIH 6204) or HIV-1 89.6 -Env (NIH 4827) pooled peptide sets (15-mers, 11 aa overlap) at a concentration of 2 mg ml 21 in RPMI 1640 medium supplemented with 2 mM glutamine, 50 U penicillin ml 21 , 50 mg streptomycin ml 21 and 5 % pooled rhesus serum in a 24-well plate for 16 h at 37 uC. The negative control was medium alone, while PMA-ionomycin (used at 20 ng ml 21 and 1 mg ml 21 , respectively) was used as a positive control. After stimulation, the non-adherent cells were collected and plated at 2610 5 cells per well in triplicate in 96-well flat-bottomed plates (Nunc) coated with anti-monkey IFN-c mAb (U-CyTech) and incubated for an additional 5 h with the same antigens added again. At the end of the incubation period, cells were lysed by adding 200 ml of ice-cold water and leaving the plates on ice for 10 min before cell debris was washed away. IFN-c production was detected using biotinylated rabbit-anti-rhesus IFN-c. Spots were visualized using a gold staining-silver enhancement technique (U-CyTech). Spots were counted using an automated ELISpot counter (AELVIS).
Intracellular cytokine staining. PBMC were incubated at 37 uC for 2 h with 2 mg anti-CD28 ml 21 and 2 mg anti-CD49d antibodies ml
(BD Pharmingen) and appropriate peptides of interest at a concentration of 1.25 mg peptide ml 21 . Medium alone was used as the negative control and staphylococcal enterotoxin B served as the positive control. To inhibit protein trafficking, cells were treated with Golgiplug (BD Pharmingen) and incubated for 16 h at 37 uC. After the incubation period, cells were washed with PBS (pH 7.4) with 1 % BSA and stained for surface markers by incubation with anti-CD3 APC , anti-CD8
APC-Cy7 and anti-CD4 PerCP for 30 min at 4 uC in the dark. Subsequently, cells were washed with PBS (pH 7.4) with 1 % BSA and fixed with Cytofix/Cytoperm solution (BD Pharmingen) for 20 min at 4 uC. The cells were then washed with permeabilization buffer (BD Pharmingen) and resuspended in permeabilization buffer containing anti-IL-2 PE , anti-IFN-c Alexa700 and TNF-a PE-Cy7 (BD Biosciences). After 30 min of incubation at 4 uC cells were washed with permeabilization buffer and fixed in 2 % paraformaldehyde solution for 16 h. Samples were measured on a FACSAria and analysed using FACS Diva software (Becton Dickinson).
Proliferation assay. Proliferative capacity upon antigen stimulation of PBMC was investigated using the 5(and 6)-carboxyfluorescein diacetate, succinimidyl ester (CFSE; Molecular Probes) proliferation assay as described previously (Lyons & Parish, 1994; Oehen & Brduscha-Riem, 1998) . Cells were stimulated with either medium alone, peptides of interest at a concentration of 1.25 mg peptide ml 21 , or 5 mg concanavalin A (ConA) ml 21 , and incubated for 6 days at 37 uC and 5 % CO 2 . Cells were stained for viability using the LIVE/ DEAD Fixable Violet Dead Cell dye (Molecular Probes) and subsequently with a mixture of CD3 APC , CD4 , CD8 and cells were fixed overnight in 2 % paraformaldehyde at 4 uC and measured on a FACSAria (Becton Dickinson). Animals in which the ConA response was less than 20 % above background were excluded from the analysis. Viability was above 95 % for all animals except DVT, for which it was 60 %.
51
Cr-release assay. Effector cells were generated from PBMC via cocultivation for 10-14 days with autologous, peptide-pulsed, feeder cells and regularly replenished with culture medium containing IL-2 during the culture period. Cytotoxicity was assessed in a classical 5 h 51 Cr-release assay. Briefly, target cells were autologous or allogeneic herpes papio-transformed B-LCL labelled with 40 mCi Na 2 51 CrO 4 (Amersham International) and peptide pools or individual peptides at 3 mg ml 21 for 16 h at 37 uC. B-LCL without peptides were used as a control. Subsequently, target cells were washed and plated at 5610 3 cells well 21 in U-shaped 96-well plates (Costar). Effector cells were added at several effector/target cell ratios in triplicate. After 5 h incubation at 37 uC, supernatants were harvested and 51 Cr release was measured using a gamma counter (Cobra 5; Packard). Spontaneous Cr release were calculated as [(experimental release2spontaneous release)/(maximum release2spontaneous release)]6100.
In vivo and ex vivo cytotoxicity assay. In vivo and ex vivo cytotoxic activity was determined by using a previously described method with modifications and using PBMC as target cells (Aichele et al., 1997) . The total amount of PBMC was split into three equal parts. Each part was labelled with a different concentration of CFSE for 5 min at room temperature. The staining reaction was stopped by adding an equal volume of FCS and the cells were washed twice and left overnight at 37 uC. Subsequently, the two populations that had been labelled at intermediate and high staining intensities were pulsed with peptide of interest at 10 mg ml 21 for 1 h at 37 uC. The third part of the cells served as a control and was not pulsed. For intravenous injection all cells were pooled and injected at 20610 6 cells ml
21
. Blood samples were collected 10 min and 24 h after injection. Ex vivo cytotoxicity was measured by co-incubation of the three different pulsed-cell populations (5610 5 cells for each population) for 10 min and 24 h. CFSE-labelled cells were measured using a FACSsort and analysed using CellQuest software (Becton Dickinson). Percentages of specific in vivo and ex vivo lysis were calculated as 1002[(number of CFSEpositive cells, specific peptide 24 h 6number of CFSE-positive cells, unpulsed 10 min /number of CFSE-positive cells, unpulsed 24 h 6number of CFSE-positive cells, specific peptide 10 min )6100].
Statistical evaluation. A Mann-Whitney test was used for comparison of cytokine and proliferative responses in CD4 and CD8 T-cells between the group of vaccinated versus 'natural' controllers. Fisher's exact test was used for comparison of SIV Gag ELISpot responses between the group of vaccinated versus 'natural' controllers in the chronic phase of the infection. Statistical analysis was performed with InStat version 3.0 (GraphPad).
